Introduction
============

With the availability of highly active antiretroviral therapy (HAART) in 1996 \[[@B1]\], a dramatic decline of AIDS-associated mortality has been observed. Accordingly, in the health management of the aging HIV-positive patient, co-morbidities such as chronic liver and cardiovascular disease are increasingly demanding clinical attention. In hepatitis C virus (HCV) co-infected patients liver-related disease has emerged as a leading cause of morbidity and mortality \[[@B2]\]. Owing to similar routes of transmission, HCV and HIV are often found in the same host. In Europe, up to one third of all HIV patients are co-infected with HCV \[[@B3]\].

The progression of chronic HCV infection to liver cirrhosis with subsequent risk for liver decompensation and hepatocellular carcinoma is substantially accelerated in HIV/HCV co-infected compared to HCV mono-infected individuals \[[@B4],[@B5]\]. The sequelae of chronic hepatitis C infection however may be stopped by successful treatment with pegylated interferon and ribavirin combination therapy so that every HIV/HCV coinfected patient should be evaluated for possible HCV treatment \[[@B6]\].

In the following review we want to summarize the current epidemiological and treatment data and discuss these with particular regard to the recently updated guidelines of the European AIDS Society in 2009 for the treatment of chronic hepatitis C infection in HIV coinfected patients.

Epidemiology
------------

Little is known on the epidemiology of HCV infection in the setting of HIV co-infection. Recently the EuroSIDA cohort, the largest prospective cohort of HIV-positive patients in Europe, was analyzed to this regard \[[@B3]\]. Within EuroSIDA, of 14 310 patients who were tested at enrollment 3 375 (24%) were anti-HCV positive at baseline. There are, however, marked differences in the prevalence of positive anti-HCV antibodies throughout Europe, reflecting differences in the proportion of HIV infections transmitted via intravenous drug abuse, still the most important risk factor for the acquisition of hepatitis C in the European HIV-positive population \[[@B7]\]. Whereas countries with a traditionally high burden of HIV-positive intravenous drug abusers have high rates of HCV co-infection with 47% and 41% of patients in Eastern and Southern Europe positive for anti-HCV antibodies, respectively, countries with MSM being the prevailing mode of HIV-transmission have lower rates of chronic HCV infection with a prevalence of anti-HCV antibody of 20% and 23% of patients in Central and Northern Europe, respectively \[[@B8]\]. These rates are clearly higher compared to the HIV-negative population, where rates of HCV-prevalence have been reported to be between 2.5 - 10% in Romania and Ukraine and 1 - 2.5% in the remaining countries of the WHO region of Europe \[[@B9]\]. With the implementation of syringe exchange programs, opioid substitution and social prevention efforts a further expansion of intravenous drug abuse related HCV infections have been successfully contained in Western Europe. For instance, in Spain a significant decrease in the overall prevalence of HCV co-infection among Spanish patients newly diagnosed with HIV has been observed, decreasing from 24% in 2000 - 2002 down to 10% in the period 2006 - 2008 \[[@B10]\]. Unfortunately in Eastern Europe, where harm reduction strategies have not yet been installed on a large scale \[[@B11]\], the HIV and HCV epidemic among intravenous drug abusers is at risk to continue unbroken in some countries \[[@B12]\].

In Western Europe, and recently the USA and Australia, new outbreaks of sexually transmitted HCV infections have been reported among men who have sex with men \[[@B7],[@B13]-[@B22]\], which continue to increase the disease burden of HCV co-infection within the HIV community and worries have been raised that this epidemic may leap over and spread within the HIV-negative MSM community as a \"new\" sexually transmitted disease. These concerns may be overstated as in a recent epidemiological survey among genito-uterine medicine (GUM) and HIV clinics in London and Brighton area on acute HCV infections among MSM, of 395 acute HCV infections between 2002 and 2006, 389 had occurred in HIV-positive patients \[[@B15]\]. Similarly Urbanus and colleagues investigated into the prevalence of HCV infection among MSM attending the sexually transmitted disease clinic in Amsterdam \[[@B20]\]. They found a significantly higher HCV prevalence among those co-infected with HIV (28/157, 18%) and history of intravenous drug use, fisting, and the use of gamma hydroxy butyrate (GHB) were all significantly associated with an increased risk for HCV infection. Only two of 532 HIV-negative MSM were found to be HCV positive, and one of these reported previous intravenous drug and these observations would be in line with past longitudinal studies of HCV serodiscordant heterosexual partnerships, where the life-time risk for sexual transmission of HCV was estimated to be \< 1% \[[@B23],[@B24]\]. Nevertheless in the MSM population due to different sexual practices the risk for sexually acquired HCV infection may be higher than among heterosexual couples and increases of acute HCV infections among HIV-negative MSM have been reported. Continued prevention efforts on sexual transmission of HCV within the MSM community, regardless of HIV serostatus, therefore only appear prudent \[[@B25]\].

Natural course of hepatitis C in HIV Co-infection
-------------------------------------------------

While hepatitis C infection does not have a relevant influence on the course of HIV infection, HIV infection accelerates the natural course of hepatitis C infection. HIV/HCV coinfected patients show a rapid progression of liver fibrosis in contrast to HCV monoinfected patients \[[@B4],[@B26]\]. Of 174 HIV/HCV coinfected patients which showed at the time-point of the first liver biopsy no or only minimal fibrosis, one third progressed more than two fibrosis stages on a scale from 0-6 (ISHAK score) \[[@B5]\]. Indeed in the HAART era end-stage liver-disease has become the main cause of morbidity and mortality in HIV/HCV coinfected patients \[[@B2]\]. Thus it is crucial for the future health of each HIV/HCV coinfected patient to assess risks and benefits of a pegylated interferon ribavirin combination therapy. A successful treatment of chronic hepatitis C has not only proven to stop the progression of liver fibrosis but to result in a survival benefit for patients \[[@B6],[@B27]\].

Pegylated interferon and ribavirin in the setting of HAART
----------------------------------------------------------

Treatment of hepatitis C infection with pegylated interferon and ribavirin may be better tolerated if started without concurrent HAART \[[@B28]\]. Therefore, if HIV infection is not advanced and there is no indication for HAART in the presence of high CD4-counts (\> 500/μl), a treatment of chronic hepatitis C infection should be started prior to initiation of HAART \[[@B29]\]. In a recent analysis of one of the largest studies on the treatment of HIV-infected with HCV infection, the APRICOT study, a relative CD4-cell count above 25% was associated with better treatment outcome than lower CD4-cell counts and initiation of HAART is strongly recommended prior to HCV therapy if the CD4-cell count is \< 350/μl \[[@B30]\]. Anti-HCV therapy in HIV co-infected individuals has been shown to be complicated by additive drug toxicities of pegylated interferon and ribavirin with the antiretroviral nucleosides didanosine \[[@B31],[@B32]\], zidovudine \[[@B33]-[@B35]\] and stavudine \[[@B36]\]. More recently, competitive phosphorylation between the guanosine nucleoside analogues abacavir and ribavirin has been hypothesized to further compromise anti-HCV treatment efficacy \[[@B37]-[@B39]\], though this effect was no longer observed in analysis restricted to patients who had received weight based doses of ribavirin \[[@B39],[@B40]\]. If feasible from the perspective of resistance and antiretroviral activity of the ART regimen, a tenofovir-based nucleoside backbone or even NRTI-free HAART should be chosen for the duration of anti-HCV therapy. In countries where tenofovir is not yet licensed or contraindications for the use of tenofovir exist, an abacavir based NRTI backbone may be considered if adequate ribavirin dosages are chosen. Therapeutic drug monitoring of ribavirin would also be an alternative to ensure that adequate ribavirin levels of \> 3.2 μg/ml are being achieved \[[@B39]\].

Diagnostic procedures for HCV in HIV Co-infection
-------------------------------------------------

Due to the increased prevalence of HCV co-infection every HIV-positive patient should be evaluated for anti-HCV antibodies at the time of first presentation and on an annual basis thereafter (Table [1](#T1){ref-type="table"}). It is important to remember that anti-HCV seroconversion after acute HCV infection may be significantly delayed in HIV-positive patients and 5% of patients had not developed anti-HCV antibodies despite ongoing viral replication for one year in a recent study \[[@B41]\]. Moreover, anti-HCV antibodies may be lost during follow-up, in particular with advanced degrees of immunode ficiency \[[@B42]\]. Therefore in patients with unexplained raised liver transaminases testing for HCV-RNA may be warranted in order to rule out occult or acute HCV-infection.

###### 

Diagnostic procedures for hepatitis C in HIV co-infection

  Diagnosis of hepatitis C
  --------------------------------------------------------------------------------------------------------------------------------------------------
  **Status of liver damage**
   Grading of fibrosis (e. g. FibroScan, liver biopsy, serum fibrosis markers^b^)
   Hepatic synthetic function (e. g. coagulation, albumin, CHE)
   Ultrasound and AFP every 6 months in cirrhotics (gastroscopy upon diagnosis of cirrhosis and every 1-2 years thereafter)
  **Before HCV treatment**
   HCV genotype and serum HCV-RNA
   Autoantibodies (ANA, LKM1)^c^
   TSH, thyroid autoantibodies
  **Monitoring of HCV treatment**
   Differential blood count and liver enzymes every 2-4 weeks
   HCV-RNA at week 4 (to evaluate rapid virological response), and weeks 12, 24, and 48 (72 if applicable) and 24 weeks after stopping HCV therapy
   CD4-count every 12 weeks
   TSH every 12 weeks

Recommendations according to the current EACS guidelines on the treatment of HIV/HCV co-infection.

a\) Low viral load defined as less than 400,000 - 500,000 IU/ml when using PegINF+RBV. There is no standard conversion formula for converting the amount of HCV-RNA reported in copies/ml to the amount reported in IU/ml. The conversion factor ranges from about one to five HCV-RNA copies per IU/ml.

b\) Serum fibrosis markers include APRI, FIB-4, Hyaluronic acid, Fibrometer, Fibrotest, Forns, Hepascore and other indices; recently more complex tests such as Fibrometer, Fibrotest and Hepascore have shown to more accurately predict liver fibrosis than simple biochemical tests such as APRI, FIB-4 or Forns.

c\) Patients with positive anti LKM or ANA with homogeneous pattern should be evaluated for concurrent autoimmune hepatitis especially in the presence of ALT elevation during treatment.

Before starting anti-HCV therapy determination of HCV genotype and HCV viral load is necessary to estimate the odds for SVR and to determine the rough grids for treatment duration. Current therapy is particularly recommended in patients with a high likelihood of achieving sustained virological response (SVR), i.e. genotypes 2 or 3 and patients infected with genotype 1 if the viral load is \< 400 000 IU/ml (Table [1](#T1){ref-type="table"}). Recently, first data suggested that the level of HCV-RNA may also influence the natural course of HCV infection in HIV-infected individuals \[[@B43]\]. In this analysis of the EuroSIDA cohort high HCV viral load above 800 000 IU/ml was associated with an increased rate of liver related death. As this is in contrast with all data from HCV-monoinfection it should, however, be discussed with caution.

Liver fibrosis staging may help to guide therapeutic decisions in co-infected patients. However, a liver biopsy is not mandatory for considering treatment of chronic HCV. In case of liver biopsy or FibroScan demonstrating lower stages of liver fibrosis (F0-1), regardless of HCV genotype, treatment can be deferred. In these cases, fibrosis assessment should be carried out at frequent intervals to monitor for fibrosis progression. Serum markers for liver fibrosis such as APRI, FIB-4, Fibrotest and others have been validated in HIV/HCV co-infected patients and may help to assess and monitor the extent of liver fibrosis. A liver disease stage assessment is especially important to perform in patients with a low chance of SVR. Patients who are diagnosed with liver cirrhosis must also be evaluated for oesophageal varices and hepatocellular carcinoma and monitored accordingly thereafter.

More recently, insulin resistance, which can be determined using the homeostasis model assessment of insulin resistance \[[@B44]\], has been repeatedly reported as a negative predictor of achievement of SVR \[[@B45],[@B46]\] and may therefore also be considered during pretreatment evaluation. Though currently there is no data suggesting that treatment of insulin resistance prior to start of pegylated interferon and ribavirin therapy actually translates into higher rates of SVR, experts recommend to effectively manage insuline resistance before treating HCV infection if possible \[[@B29]\].

Determination of antinuclear (ANA) and liver kidney microsome (LKM) autoantibodies can help to identify underlying autoimmune hepatitis \[[@B47]\], a disease which may significantly worsen under interferon therapy. Therefore patients with a homogenous pattern of ANA or positive anti-LKM should be further evaluated for autoimmune hepatitis, especially in the presence of ALT elevation during treatment. Similarly screening for thyroid autoantibodies will help to identify individuals at particular risk for the development of autoimmune thyroiditis \[[@B48]-[@B50]\]. Controlling thyroid stimulating hormone (TSH) at baseline and every 12 weeks under therapy helps to identify patients with thyroid dysfunction under interferon therapy and allows early therapeutic intervention.

During interferon and ribavirin therapy, the most common adverse events observed are flu-like symptoms, anemia, leucopenia and mood disorders. Flu-like symptoms may be severe and can require concomitant therapy with non-steroidal anti-inflammatory drugs (NSAID). Starting NSAID a few hours before the weekly injection of pegylated interferon and continue for another 24 - 48 hours after the injection may help to stop or relief symptoms in severely affected individuals. The maximum hemoglobin loss is usually observed within the first 12 weeks of interferon and ribavirin therapy and frequent monitoring at 1 - 2 week intervals is advised during this time in order to timely adjust ribavirin doses accordingly (Table [1](#T1){ref-type="table"}). Particular attention must be given to patients with reduced creatinine clearance who have a higher risk for ribavirin associated anemia. In case of creatinine clearance \< 50 ml/min ribavirin therapy should only be started with reduced doses and after consultation with an experienced hepatologist and/or nephrologist. Determination of week 2 hemoglobin concentrations may help to estimate the full extent of ribavirin induced anemia and allow dose modifications in patients at risk earlier \[[@B51]\]. Patients with preexisting coronary heart disease are more vulnerable to ribavirin associated anemia and subsequently lower thresholds of hemoglobin decay must be taken into account when assessing the need for ribavirin dose reductions. In patients with persisting anemia despite ribavirin dose reductions interferon induced auto-immune anemia should be a differential diagnosis. Observed leucopenia and thrombocytopenia are mainly due to the interferon associated bone marrow suppression and may require dose adaptations according to the summary of product characteristics of the interferon used.

Mood disorders are frequently encountered in HCV-positive patients undergoing interferon based therapies. Patients with preexistent psychiatric comorbidities should be evaluated prior and ideally monitored during interferon therapy by a psychiatrist. In case mood disorders such as depression occur during the treatment course, pharmacologic interventions have shown to be of great success and few patients have to stop interferon therapy due to psychiatric adverse events \[[@B52]\].

Therapy of hepatitis C infection
--------------------------------

Current treatment of choice is pegylated interferon in combination with ribavirin. The standard dose for pegylated interferon alfa-2a is 180 μg once weekly, and for pegylated interferon alfa-2b it is 1.5 μg/kg body-weight once weekly. In contrast to HCV monoinfected patients in HIV/HCV coinfected patients a bodyweight-adapted dosage of ribavirin is recommended for all HCV genotypes because historical comparison demonstrated superiority of a weight-adapted dosage also in patients with genotype 2 or 3 infections \[[@B53]\]. Patients with a bodyweight \< 75 kg should receive 1000 mg ribavirin, patients ≥ 75 kg 1200 mg per day.

The duration of treatment should be individualized according to HCV genotype, baseline HCV viral load, and response to treatment (Figure [1](#F1){ref-type="fig"}, \[[@B29]\]). Based on the data from the PRESCO trial patients with genotype 1 and 4 infections should be treated for 48 weeks in case of a rapid HCV-RNA clearance below the level of detection at week 4 (rapid virological response). In all other cases treatment should be prolonged to 72 weeks \[[@B54]\]. On the other side, in patients with a rapid virological response, i.e. a negative HCV-RNA at week 4 and a genotype 2 or 3 infection, the overall treatment course may be reduced to 24 weeks. However, this should be only done in patients with a low baseline HCV viral load \< 400 000 I.U./ml and only minimal liver fibrosis \[[@B55]\]. All other patients with a genotype 2 or 3 infection should be treated for 48 weeks. Treatment may be stopped if insufficient virological response is observed. Thus, if the decay of HCVRNA is less than 2 log10 at week 12 or HCV-RNA is still positive at week 24 treatment should be stopped. Under these treatment modalities, the response rates in HIV/HCV coinfected patients have significantly improved over the years, closing the gaps between HCV monoinfected and HIV/HCV coinfected patients (Table [2](#T2){ref-type="table"}). Currently in HIV/HCV coinfected patients a sustained virological response, i.e. a negative HCV-RNA 24 weeks after stop of treatment, is observed in genotype 1 or 4 infections in about 35% and in genotype 2 and 3 infections in about 70% of patients \[[@B56]\].

![**Guidelines of the European AIDS Society (EACS) for the treatment of chronic hepatitis C infection in HIV/HCV coinfected individuals**. W = week, neg = negative, pos = positive, G = HCV-genotype.](2047-783X-14-12-507-1){#F1}

###### 

Studies on the treatment of chronic HCV infection in HIV/HCV co-infected patients

  Study                                     Number patients^†^   Study type                                         PegIFN Therapy   Patient characteristics   SVR rates                                 
  ----------------------------------------- -------------------- -------------------------------------------------- ---------------- ------------------------- ----------- ----- ---------- ---- ------- --------
  Laguno et al. 2004 \[[@B61]\]             52                   prospective randomized controlled clinical trial   24 - 48          800 - 1200                47\*        49    82         44   38      53
                                                                                                                                                                                                         
  Nunez et al. 2007 \[[@B62]\]              389                  prospective clinical trial                         24 - 72          1000 - 1200               67\*        49    90         50   35      72
                                                                                                                                                                                                         
  Laguno et al. 2009 \[[@B63]\]             182                  prospective randomized controlled clinical trial   48               800 - 1200                59\*        45    76         44   30      66
                                                                                                                                                                                                         
  Torriani et al. 2004 \[[@B64]\]           289                  prospective randomized controlled clinical trial   48               800                       72\*        61    62         40   29^‡^   62
                                                                                                                                                                                                         
  Mira et al. 2009 \[[@B65]\]               542                  observational cohort study                         24 - 48          600 - 1500                58\*        54    85         38   25      63
                                                                                                                                                                                                         
  Rodriguez-Torres et al. 2009 \[[@B66]\]   410                  prospective randomized controlled clinical trial   48               800 - 1200                80\*        100   n.r.       \-   21      \-
                                                                                                                                                                                                         
  Voigt et al. 2005 \[[@B67]\]              122                  prospective clinical trial                         24 - 48          800                       45\*        56    61         25   18      44
                                                                                                                                                                                                         
  Berenguer et al. 2009 \[[@B68]\]          557                  observational cohort study                         \#               \#                        61\*        51    80         32   17      45
                                                                                                                                                                                                         
  Carrat et al. 2004 \[[@B69]\]             205                  prospective randomized controlled clinical trial   48               800                       63\*        48    80         27   17      44^\$^
                                                                                                                                                                                                         
  Chung et al. 2004 \[[@B70]\]              66                   prospective randomized controlled clinical trial   48               600 - 1000^\$^            83\*        77    not rep.   27   14^‡^   73^\$^

^†^number of patients who received pegylated interferon;

\* high viral load defined as: Chung et al. \> 1 000 000 IU/ml; Rodriguez-Torres et al. \> 800 000 IU/ml; Voigt et al., Laguno et al. Torriani et al. \> 800 000 IU/ml; Mira et al., Laguno et al.,\*Nunez et al. HCV-RNA \> 600 000 IU/ml; Berenguer et al., Carrat et al. \> 500 000 IU/ml;

^‡^only reported for GT1 infections;

^\#^reported as median 13.3 and 14.0 mg/kg body weight/day and median 8 and 11 months of treatment duration for the respective treatment group; \$ Carrate et al. SVR rate reported for GT 2,3 or 5 infections: Chung et al. SVR rate reported for non-1 genotypes;

^§^dose escalating regimen, starting at 600 mg; n.r. rot reported in the abstract

In patients with acute HCV infection, HCV therapy is recommended if HCV-RNA is confirmed positive (1 week apart) by week 12 post HCV transmission, as SVR rates following treatment of acute HCV-infection are higher than for treatment of chronic HCV \[[@B57]\]. Most experts recommend therapy for 24 weeks with Peg-INF and ribavirin; however the duration of therapy and use of ribavirin is currently under discussion. HCV-RNA levels at week 4 and 12 may help to guide treatment duration \[[@B58]\].

Non-responder
-------------

After failure of a modern pegylated interferon therapy with weight based ribavirin dosage according to present guidelines there is at present no reasonable treatment option for HIV/HCV coinfected patients. An interferon maintenance therapy in order to delay or stop the progression of liver fibrosis has been discussed in the past as a possible treatment option. However, within the two largest studies on this issue (HALT-C for HCV monoinfected and SLAM-C for HCV/HIV coinfected patients \[[@B59],[@B60]\]) this treatment option did not result in any benefit for the patients so that no continuation of interferon treatment is useful after treatment failure.

Patients who have been treated in the past with a standard interferon (not pegylated) or without/without sufficient dosage of ribavirin should be individually discussed with an experienced hepatologist/HIV specialist in how far a new treatment with pegylated interferon in combination with ribavirin may be useful and may result in sustained virological response. At present a whole array of new small molecules for the treatment of hepatitis C is in clinical development. Many of the new drugs - like the most advanced in clinical development telaprevir and boceprevir - are, however, metabolized via the cytochrome P-450 system so that relevant pharmacokinetic interactions with antiretroviral drugs, in particular ritonavir boosted protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are to be expected. In addition most HCV-protease inhibitors do not seem to have marked antiviral efficacy against HCV genotype 3 and 4 and are designed for highest efficacy in the difficult to treat genotype 1 infection. Thus at present it is not foreseeable when these new compounds will be available for HIV/HCV coinfected patients in clinical routine.

Conclusion
==========

Due to the enhanced risk for progression of chronic hepatitis C, every HIV/HCV coinfected patient should be evaluated for treatment with a pegylated interferon ribavirin combination therapy. The standard of care for the treatment of chronic HCV infection in HIV-infected remains a pegylated interferon in combination with weight-adapted ribavirin. The duration of therapy is dependent on HCV genotype, baseline HCV viral load, and treatment response. In the last years, due to the introduction of weight based ribavirin and an overall prolongation of the course of treatment treatment response rates in HIV/HCV coinfected patients have been enhanced and are coming closer to response rates observed in HCV monoinfected patients. Currently treatment response rates in patients with genotype 1 and 4 infections and 2 and 3 infections are observed in 35% and 70% of patients respectively.

Higher CD4-cell counts are associated with higher treatment response rates. Thus HAART should not be withheld from patients due to concerns of drug related hepatotoxicity and in patients with reduced CD4cell counts HAART should be started first. Under concomitant use of HAART and pegylated interferon and ribavirin combination therapy drug to drug interactions and cumulated toxicity between nucleoside analogues and anti-HCV therapy may be observed and HAART should be adjusted accordingly. Importantly concomitant didanosine use is contraindicated and zidovudine and stavudine should be avoided if possible.

The development of new drugs for the treatment of chronic hepatitis C represents a promising perspective also for HIV positive patients. However, due to necessary pharmacokinetic interaction studies, these substances will probably reach clinical routine for HIV patients later than HCV monoinfected patients. Therefore at present waiting for new substances is not an alternative to a modern pegylated interferon/ribavirin therapy.
